Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Sees Potential to Lower Medication Doses Using Advanced Drug Delivery

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) has developed DehydraTECH™, a drug delivery platform that can be applied to various ingestible products such as foods, beverages, oral suspensions, tablets, capsules and more. An article discussing the company’s innovative drug delivery technology reads: “Lexaria’s DehydraTECH™ oral digestion technology is a ‘back office’ process that allows non-psychoactive cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and nicotine to be absorbed at much higher rates. The company has been working with the National Research Council of Canada (“NRC”), an agency of the Canadian federal government, to explore the effects of its technology. Lexaria’s superior delivery system offers the promise of potentially reducing required doses of these substances, since less of them goes to waste. The technology also speeds up delivery. It can deliver payload molecules to the bloodstream in 15-25 minutes, as opposed to the 60-90 minutes required for current methods, and is already in use in a number of consumer products. The technology is already attracting the attention of Big Pharma, and Lexaria is in negotiations with major pharmaceutical companies to license its technology.”

To view the full article, visit http://ibn.fm/Rwsg9

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.LexariaEnergy.com.

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
[email protected]

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php



This post first appeared on Monaker Group, Inc. (MKGI) Carves Niche In Explosi, please read the originial post: here

Share the post

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Sees Potential to Lower Medication Doses Using Advanced Drug Delivery

×

Subscribe to Monaker Group, Inc. (mkgi) Carves Niche In Explosi

Get updates delivered right to your inbox!

Thank you for your subscription

×